Breast cancer is a highly metastatic disease even after surgical removal of the primary tumor. Metastasis is the main cause of death in breast cancer patients.
Objectives: The aim of the study was to assess the concentration of E-selectin in serum and tissue from breast cancer patients and women suffering from benign breast disease to determine its prognostic value in these diseases.
Material and methods: This study was conducted on three groups of patients: Group A included 92 breast cancer patients, Group B included 25 patients with benign breast and group C (the control group) included 16 subjects.
Blood samples were withdrawn for the estimation of serum E-selectin by ELISA and the gene expression of E-selectin was examined in Breast tissue samples.
Results: The results showed that serum level of E-selectin was highly significantly increased in malignant group as compared to benign and control groups (P < 0.05), it increased with the progression of disease. E-selectin serum level showed non-significant difference between benign and control groups. E-selectin gene was expressed in 76.1% in malignant tissues, in 44.0 % in benign tissues and in only one case in control group (6.2%). These results show highly significant difference between the diseased groups and the controls. The expression of E-selectin significantly correlated with aggressive tumor behavior.
In conclusion, we found that the assessment of the adhesion molecule E-selectin in women with breast cancer can be added to the panel of tests that monitor the progress of the disease.
Key words: Adhesion molecules, E-selectin, Breast Carcinoma, Tumor Grade, Prognosis, Molecular types, Gene expression